The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Noninvasive Cancer Diagnostics Market Research Report 2025
Synopsis
Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.
The global Noninvasive Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics.
Report Scope
The Noninvasive Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Noninvasive Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Precision Therapeutics, Inc. (U.S.)
A&G Pharmaceutical, Inc. (U.S.)
Affymetrix Inc. (U.S.)
AVIVA Biosciences Corporation (U.S.)
BIOVIEW Inc. (U.S.)
Laboratory Corporation of America Holdings (LabCorp) (U.S.)
Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
Digene Corporation (U.S.)
Gen-Probe Incorporated (U.S.)
IVDiagnostics, Inc. (U.S.)
Segment by Type
Clinical Chemistry
Immunochemistry/Immunoassay
Molecular Diagnostics
Others
Segment by Application
Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.
The global Noninvasive Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics.
Report Scope
The Noninvasive Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Noninvasive Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Precision Therapeutics, Inc. (U.S.)
A&G Pharmaceutical, Inc. (U.S.)
Affymetrix Inc. (U.S.)
AVIVA Biosciences Corporation (U.S.)
BIOVIEW Inc. (U.S.)
Laboratory Corporation of America Holdings (LabCorp) (U.S.)
Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
Digene Corporation (U.S.)
Gen-Probe Incorporated (U.S.)
IVDiagnostics, Inc. (U.S.)
Segment by Type
Clinical Chemistry
Immunochemistry/Immunoassay
Molecular Diagnostics
Others
Segment by Application
Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Noninvasive Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Clinical Chemistry
1.2.3 Immunochemistry/Immunoassay
1.2.4 Molecular Diagnostics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Noninvasive Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Blood Cancer
1.3.4 Lung Cancer
1.3.5 Breast Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Noninvasive Cancer Diagnostics Market Perspective (2019-2030)
2.2 Noninvasive Cancer Diagnostics Growth Trends by Region
2.2.1 Global Noninvasive Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Noninvasive Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Noninvasive Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Noninvasive Cancer Diagnostics Market Dynamics
2.3.1 Noninvasive Cancer Diagnostics Industry Trends
2.3.2 Noninvasive Cancer Diagnostics Market Drivers
2.3.3 Noninvasive Cancer Diagnostics Market Challenges
2.3.4 Noninvasive Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Noninvasive Cancer Diagnostics Players by Revenue
3.1.1 Global Top Noninvasive Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Noninvasive Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Noninvasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Noninvasive Cancer Diagnostics Revenue
3.4 Global Noninvasive Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Noninvasive Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Noninvasive Cancer Diagnostics Revenue in 2023
3.5 Noninvasive Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Noninvasive Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Noninvasive Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Noninvasive Cancer Diagnostics Breakdown Data by Type
4.1 Global Noninvasive Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Noninvasive Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Noninvasive Cancer Diagnostics Breakdown Data by Application
5.1 Global Noninvasive Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Noninvasive Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Noninvasive Cancer Diagnostics Market Size (2019-2030)
6.2 North America Noninvasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Noninvasive Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Noninvasive Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Noninvasive Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Noninvasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Noninvasive Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Noninvasive Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Noninvasive Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Noninvasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Noninvasive Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Noninvasive Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Precision Therapeutics, Inc. (U.S.)
11.1.1 Precision Therapeutics, Inc. (U.S.) Company Detail
11.1.2 Precision Therapeutics, Inc. (U.S.) Business Overview
11.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
11.1.4 Precision Therapeutics, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.1.5 Precision Therapeutics, Inc. (U.S.) Recent Development
11.2 A&G Pharmaceutical, Inc. (U.S.)
11.2.1 A&G Pharmaceutical, Inc. (U.S.) Company Detail
11.2.2 A&G Pharmaceutical, Inc. (U.S.) Business Overview
11.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
11.2.4 A&G Pharmaceutical, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.2.5 A&G Pharmaceutical, Inc. (U.S.) Recent Development
11.3 Affymetrix Inc. (U.S.)
11.3.1 Affymetrix Inc. (U.S.) Company Detail
11.3.2 Affymetrix Inc. (U.S.) Business Overview
11.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
11.3.4 Affymetrix Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.3.5 Affymetrix Inc. (U.S.) Recent Development
11.4 AVIVA Biosciences Corporation (U.S.)
11.4.1 AVIVA Biosciences Corporation (U.S.) Company Detail
11.4.2 AVIVA Biosciences Corporation (U.S.) Business Overview
11.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Introduction
11.4.4 AVIVA Biosciences Corporation (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.4.5 AVIVA Biosciences Corporation (U.S.) Recent Development
11.5 BIOVIEW Inc. (U.S.)
11.5.1 BIOVIEW Inc. (U.S.) Company Detail
11.5.2 BIOVIEW Inc. (U.S.) Business Overview
11.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
11.5.4 BIOVIEW Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.5.5 BIOVIEW Inc. (U.S.) Recent Development
11.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
11.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Company Detail
11.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
11.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Introduction
11.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.6.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Development
11.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
11.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Company Detail
11.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
11.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
11.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.7.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Development
11.8 Digene Corporation (U.S.)
11.8.1 Digene Corporation (U.S.) Company Detail
11.8.2 Digene Corporation (U.S.) Business Overview
11.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Introduction
11.8.4 Digene Corporation (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.8.5 Digene Corporation (U.S.) Recent Development
11.9 Gen-Probe Incorporated (U.S.)
11.9.1 Gen-Probe Incorporated (U.S.) Company Detail
11.9.2 Gen-Probe Incorporated (U.S.) Business Overview
11.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Introduction
11.9.4 Gen-Probe Incorporated (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.9.5 Gen-Probe Incorporated (U.S.) Recent Development
11.10 IVDiagnostics, Inc. (U.S.)
11.10.1 IVDiagnostics, Inc. (U.S.) Company Detail
11.10.2 IVDiagnostics, Inc. (U.S.) Business Overview
11.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
11.10.4 IVDiagnostics, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024)
11.10.5 IVDiagnostics, Inc. (U.S.) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Noninvasive Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Clinical Chemistry
Table 3. Key Players of Immunochemistry/Immunoassay
Table 4. Key Players of Molecular Diagnostics
Table 5. Key Players of Others
Table 6. Global Noninvasive Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Noninvasive Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Noninvasive Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Noninvasive Cancer Diagnostics Market Share by Region (2019-2024)
Table 10. Global Noninvasive Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Noninvasive Cancer Diagnostics Market Share by Region (2025-2030)
Table 12. Noninvasive Cancer Diagnostics Market Trends
Table 13. Noninvasive Cancer Diagnostics Market Drivers
Table 14. Noninvasive Cancer Diagnostics Market Challenges
Table 15. Noninvasive Cancer Diagnostics Market Restraints
Table 16. Global Noninvasive Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Noninvasive Cancer Diagnostics Market Share by Players (2019-2024)
Table 18. Global Top Noninvasive Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics as of 2023)
Table 19. Ranking of Global Top Noninvasive Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Noninvasive Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Noninvasive Cancer Diagnostics Product Solution and Service
Table 23. Date of Enter into Noninvasive Cancer Diagnostics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Noninvasive Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Noninvasive Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 27. Global Noninvasive Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Noninvasive Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 29. Global Noninvasive Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Noninvasive Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 31. Global Noninvasive Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Noninvasive Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 33. North America Noninvasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Noninvasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Noninvasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Noninvasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Noninvasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Noninvasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Noninvasive Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Noninvasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Noninvasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Noninvasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Noninvasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Precision Therapeutics, Inc. (U.S.) Company Detail
Table 49. Precision Therapeutics, Inc. (U.S.) Business Overview
Table 50. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 51. Precision Therapeutics, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 52. Precision Therapeutics, Inc. (U.S.) Recent Development
Table 53. A&G Pharmaceutical, Inc. (U.S.) Company Detail
Table 54. A&G Pharmaceutical, Inc. (U.S.) Business Overview
Table 55. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 56. A&G Pharmaceutical, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 57. A&G Pharmaceutical, Inc. (U.S.) Recent Development
Table 58. Affymetrix Inc. (U.S.) Company Detail
Table 59. Affymetrix Inc. (U.S.) Business Overview
Table 60. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 61. Affymetrix Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 62. Affymetrix Inc. (U.S.) Recent Development
Table 63. AVIVA Biosciences Corporation (U.S.) Company Detail
Table 64. AVIVA Biosciences Corporation (U.S.) Business Overview
Table 65. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product
Table 66. AVIVA Biosciences Corporation (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 67. AVIVA Biosciences Corporation (U.S.) Recent Development
Table 68. BIOVIEW Inc. (U.S.) Company Detail
Table 69. BIOVIEW Inc. (U.S.) Business Overview
Table 70. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 71. BIOVIEW Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 72. BIOVIEW Inc. (U.S.) Recent Development
Table 73. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Company Detail
Table 74. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
Table 75. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product
Table 76. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 77. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Development
Table 78. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Company Detail
Table 79. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
Table 80. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 81. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 82. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Development
Table 83. Digene Corporation (U.S.) Company Detail
Table 84. Digene Corporation (U.S.) Business Overview
Table 85. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product
Table 86. Digene Corporation (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 87. Digene Corporation (U.S.) Recent Development
Table 88. Gen-Probe Incorporated (U.S.) Company Detail
Table 89. Gen-Probe Incorporated (U.S.) Business Overview
Table 90. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product
Table 91. Gen-Probe Incorporated (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 92. Gen-Probe Incorporated (U.S.) Recent Development
Table 93. IVDiagnostics, Inc. (U.S.) Company Detail
Table 94. IVDiagnostics, Inc. (U.S.) Business Overview
Table 95. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 96. IVDiagnostics, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 97. IVDiagnostics, Inc. (U.S.) Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Noninvasive Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Noninvasive Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Clinical Chemistry Features
Figure 4. Immunochemistry/Immunoassay Features
Figure 5. Molecular Diagnostics Features
Figure 6. Others Features
Figure 7. Global Noninvasive Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Noninvasive Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 9. Solid Tumors Case Studies
Figure 10. Blood Cancer Case Studies
Figure 11. Lung Cancer Case Studies
Figure 12. Breast Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Noninvasive Cancer Diagnostics Report Years Considered
Figure 15. Global Noninvasive Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Noninvasive Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Noninvasive Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 18. Global Noninvasive Cancer Diagnostics Market Share by Players in 2023
Figure 19. Global Top Noninvasive Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Noninvasive Cancer Diagnostics Revenue in 2023
Figure 21. North America Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Noninvasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 23. United States Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Noninvasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 27. Germany Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Noninvasive Cancer Diagnostics Market Share by Region (2019-2030)
Figure 35. China Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Noninvasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 43. Mexico Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Noninvasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 47. Turkey Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Noninvasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Precision Therapeutics, Inc. (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 50. A&G Pharmaceutical, Inc. (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 51. Affymetrix Inc. (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 52. AVIVA Biosciences Corporation (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 53. BIOVIEW Inc. (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 54. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 55. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 56. Digene Corporation (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 57. Gen-Probe Incorporated (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 58. IVDiagnostics, Inc. (U.S.) Revenue Growth Rate in Noninvasive Cancer Diagnostics Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
